IN2014DN06869A - - Google Patents

Info

Publication number
IN2014DN06869A
IN2014DN06869A IN6869DEN2014A IN2014DN06869A IN 2014DN06869 A IN2014DN06869 A IN 2014DN06869A IN 6869DEN2014 A IN6869DEN2014 A IN 6869DEN2014A IN 2014DN06869 A IN2014DN06869 A IN 2014DN06869A
Authority
IN
India
Prior art keywords
subclasses
classes
pharmaceutically acceptable
treatment
pharmaceutical compositions
Prior art date
Application number
Inventor
Bijoy Panicker
Rama K Mishra
Dawoon Jung
Lambertus J W M Oehlen
Dong Sung Lim
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of IN2014DN06869A publication Critical patent/IN2014DN06869A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof as described generally and in classes and subclasses herein and additionally provides pharmaceutical compositions thereof and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
IN6869DEN2014 2012-01-26 2013-01-26 IN2014DN06869A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261632582P 2012-01-26 2012-01-26
PCT/US2013/023324 WO2013112959A1 (en) 2012-01-26 2013-01-26 Antifibrotic compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN06869A true IN2014DN06869A (en) 2015-05-22

Family

ID=48873985

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6869DEN2014 IN2014DN06869A (en) 2012-01-26 2013-01-26

Country Status (14)

Country Link
US (4) US9040555B2 (en)
EP (2) EP3604307A1 (en)
JP (1) JP6152389B2 (en)
CN (1) CN104136436B (en)
AU (1) AU2013211888B2 (en)
CA (1) CA2862692C (en)
DK (1) DK2807160T3 (en)
ES (1) ES2748873T3 (en)
HU (1) HUE046368T2 (en)
IL (2) IL233727A (en)
IN (1) IN2014DN06869A (en)
PL (1) PL2807160T3 (en)
PT (1) PT2807160T (en)
WO (1) WO2013112959A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06869A (en) 2012-01-26 2015-05-22 Angion Biomedica Corp
US9597321B2 (en) * 2012-01-26 2017-03-21 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US20150105380A1 (en) * 2013-09-23 2015-04-16 Angion Biomedica Corp. Methods and uses of compounds for treating disease
CN104387385B (en) * 2014-11-14 2016-03-23 苏州和健医药科技有限公司 6-carboxylate methyl ester-2-oxygen-7-azaindole and preparation method thereof and application
CA3004595A1 (en) * 2015-11-12 2017-05-18 Lg Chem, Ltd. Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
ES2836255T3 (en) 2016-03-08 2021-06-24 Respivert Ltd Indole derivatives and their use as protein kinase inhibitors
JP2019519543A (en) * 2016-06-07 2019-07-11 デルマヴァント サイエンシーズ ゲーエムベーハーＤｅｒｍａｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Topical formulations of PDE-4 inhibitors and methods of their use
AU2020386913A1 (en) * 2019-11-20 2022-06-02 Angion Biomedica Corp. Methods for treating inflammatory bowel disease
EP4175634A4 (en) * 2020-07-01 2024-08-21 Angion Biomedica Corp. SOLID FORMS OF (Z)-METHYL 3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLENE)-2-OXO-2, 3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLATE AND SALTS THEREOF
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
WO2022006277A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Methods for treatment of fibrotic kidney diseases
US20240082271A1 (en) * 2021-01-13 2024-03-14 Phost’In Therapeutics Methods of Treatment of Fibrotic Diseases
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999065875A1 (en) 1998-06-17 1999-12-23 Geron Corporation Telomerase inhibitors
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
UA75054C2 (en) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
CA2407799A1 (en) * 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
EP1581309A4 (en) 2002-11-15 2009-07-29 Exelixis Inc Kinase modulators
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2008138232A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
WO2008138184A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
TWI440638B (en) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd Heterocyclic compound and pharmaceutical composition thereof
WO2010088000A2 (en) * 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
JP2011213697A (en) * 2010-04-02 2011-10-27 Astellas Pharma Inc Anthracycline compound
US9597321B2 (en) * 2012-01-26 2017-03-21 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
IN2014DN06869A (en) * 2012-01-26 2015-05-22 Angion Biomedica Corp
US20150105380A1 (en) 2013-09-23 2015-04-16 Angion Biomedica Corp. Methods and uses of compounds for treating disease

Also Published As

Publication number Publication date
EP2807160A1 (en) 2014-12-03
AU2013211888B2 (en) 2017-08-31
US10195184B2 (en) 2019-02-05
PL2807160T3 (en) 2020-03-31
IL251974A0 (en) 2017-06-29
US20180008581A1 (en) 2018-01-11
JP6152389B2 (en) 2017-06-21
HUE046368T2 (en) 2020-02-28
WO2013112959A9 (en) 2015-01-15
EP3604307A1 (en) 2020-02-05
CN104136436A (en) 2014-11-05
CA2862692C (en) 2021-05-04
IL233727A (en) 2017-05-29
HK1203502A1 (en) 2015-10-30
WO2013112959A1 (en) 2013-08-01
PT2807160T (en) 2019-10-28
WO2013112959A8 (en) 2013-09-12
CN104136436B (en) 2019-01-01
US20140371234A1 (en) 2014-12-18
US20190125731A1 (en) 2019-05-02
EP2807160A4 (en) 2014-12-24
US20200069662A1 (en) 2020-03-05
IL251974B (en) 2020-08-31
AU2013211888A1 (en) 2014-08-14
CA2862692A1 (en) 2013-08-01
EP2807160B1 (en) 2019-07-24
ES2748873T3 (en) 2020-03-18
DK2807160T3 (en) 2019-10-14
JP2015505543A (en) 2015-02-23
US11504359B2 (en) 2022-11-22
US9040555B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
IN2014DN06869A (en)
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2014DN09352A (en)
IN2014DN09348A (en)
IN2014DN10670A (en)
PH12018500061A1 (en) Oxysterols and methods of use thereof
IN2015DN01156A (en)
PH12014501469A1 (en) Bromodomain inhibitors
MX390302B (en) Oxysterols and methods of use thereof
PH12016500024A1 (en) Bromodomain inhibitor
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2015011984A (en) Dihydro-pyrrolopyridinone bromodomain inhibitors.
MX2014012695A (en) Isoindolone derivatives.
IN2014MN02598A (en)
IN2014CN02806A (en)
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TW201613864A (en) Novel compounds
MX2016007440A (en) Bromodomain inhibitors.
IN2014DN09347A (en)
MX2021010297A (en) Human plasma kallikrein inhibitors.
MX362879B (en) Novel uses.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2015001657A (en) Lpar - substituted cyanopyrazole compounds.
NZ780408A (en) Human plasma kallikrein inhibitors